Calton & Associates’s Immunomedics Inc IMMU Stock Holding History

Calton & Associates’s Portfolio IMMU Stock Details IMMU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-44,550	Closed	-$3.79M	–	402
2020 Q3	$3.79M	Sell	44,550 -7,800	-15%	-$394K	0.78%	22
2020 Q2	$1.85M	Sell	52,350 -15,800	-23%	-$462K	0.4%	53
2020 Q1	$919K	Buy	68,150 +20,000	+42%	+$337K	0.23%	83
2019 Q4	$1.02M	Buy	+48,150	New	+$849K	0.2%	94
2018 Q3	–	Sell	-12,500	Closed	-$294K	–	320
2018 Q2	$294K	Hold	12,500	–	–	0.09%	192
2018 Q1	$183K	Buy	12,500 +5,000	+67%	+$81.7K	0.05%	326
2017 Q4	$135K	Buy	+7,500	New	+$88.5K	0.03%	420

Calton & Associates's IMMU Position: Q4 2020 in Review

Calton & Associates sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 44,550 shares — an estimated $3.79M sold.

Calton & Associates first reported a position in IMMU in Q4 2017 and held it in 7 quarters. The position peaked at $3.79M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

Calton & Associates reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
Calton & Associates sold 44,550 Immunomedics Inc shares in Q4 2020, an estimated $3.79M.
Calton & Associates first reported a position in Immunomedics Inc in Q4 2017 and held it in 7 quarters.
Calton & Associates's Immunomedics Inc position peaked at $3.79M in Q3 2020.
0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on Calton & Associates's 13F filing for Q4 2020, filed 25 Jan 2021.